Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: A real-world study at Khyber Teaching Hospital, Peshawar, Pakistan

Objectives: To evaluate the effectiveness, tolerability, and safety profile of tofacitinib in patients with rheumatoid arthritis. Methodology: A retrospective observational cohort study using routine clinical records from May 2, 2023 to December 31, 2025. Adults meeting the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria were included. Effectiveness was assessed by change in DAS28 disease activity category and by remission or low disease activity at follow-up. Paired category changes used Wilcoxon signed-rank and marginal homogeneity tests. Logistic regression examined predictors of remission. Results: The cohort included 319 patients, mean age 41.23 ± 12.40 years, 71.8% women. Baseline disease activity was high in 87.1% and moderate in 12.9%, with no remission. At follow-up, 47.0% achieved remission and 36.7% achieved low disease activity, while high activity fell to 6.3% with p less than 0.001. Male sex showed lower odds of remission with adjusted odds ratio 0.599 and 95% confidence interval 0.362 to 0.990. Adverse events were documented in 9.4%. Treatment was recorded as well tolerated in 93.7%, and 15.7% discontinued. Common events were raised ALT 6.3%, lipid abnormalities 3.1%, and herpes zoster 3.1%. Myocardial infarction 1.3% and thrombosis 0.9% were rare. Conclusion: In this tertiary-care cohort, tofacitinib was linked to a large shift toward remission or low disease activity with a manageable recorded safety profile. Use requires baseline risk review and follow-up monitoring.

Authors

Institutions

Publication Details

Journal
Pakistan Journal of Medical Sciences
Published
2026-11-19
DOI
https://doi.org/10.12669/pjms.42.12.16136
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: A real-world study at Khyber Teaching Hospital, Peshawar, Pakistan

Alam Zeb, Moath Ahmad Abdullah Almuradi, Mohammad Haroon, Inam Ullah Khan
Pakistan Journal of Medical Sciences
Rheumatoid Arthritis Research and Therapies
article

Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: A real-world study at Khyber Teaching Hospital, Peshawar, Pakistan

Alam Zeb, Moath Ahmad Abdullah Almuradi, Mohammad Haroon, Inam Ullah Khan
article en

Abstract

Objectives: To evaluate the effectiveness, tolerability, and safety profile of tofacitinib in patients with rheumatoid arthritis. Methodology: A retrospective observational cohort study using routine clinical records from May 2, 2023 to December 31, 2025. Adults meeting the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria were included. Effectiveness was assessed by change in DAS28 disease activity category and by remission or low disease activity at follow-up. Paired category changes used Wilcoxon signed-rank and marginal homogeneity tests. Logistic regression examined predictors of remission. Results: The cohort included 319 patients, mean age 41.23 ± 12.40 years, 71.8% women. Baseline disease activity was high in 87.1% and moderate in 12.9%, with no remission. At follow-up, 47.0% achieved remission and 36.7% achieved low disease activity, while high activity fell to 6.3% with p less than 0.001. Male sex showed lower odds of remission with adjusted odds ratio 0.599 and 95% confidence interval 0.362 to 0.990. Adverse events were documented in 9.4%. Treatment was recorded as well tolerated in 93.7%, and 15.7% discontinued. Common events were raised ALT 6.3%, lipid abnormalities 3.1%, and herpes zoster 3.1%. Myocardial infarction 1.3% and thrombosis 0.9% were rare. Conclusion: In this tertiary-care cohort, tofacitinib was linked to a large shift toward remission or low disease activity with a manageable recorded safety profile. Use requires baseline risk review and follow-up monitoring.

Pakistan Journal of Medical SciencesVol. 42(12)
Khyber Teaching Hospital (PK)
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon